-
Je něco špatně v tomto záznamu ?
Postoperative Radiotherapy for pT1- and pT2-Classified Squamous Cell Carcinoma of the External Auditory Canal
CH. Nabuurs, W. Kievit, CRR. Leemans, CFGM. Smit, MWM. van den Brekel, RJ. Pauw, BFAM. van der Laan, JC. Jansen, M. Lacko, WW. Braunius, C. Dai, X. Shi, G. Danesi, J. Bouček, D. Borsetto, S. Gowrishankar, R. Kania, C. Jourdaine, TTG. Jansen, J....
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
39682212
DOI
10.3390/cancers16234026
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: There is no consensus regarding the indication for postoperative radiotherapy (PORT) for T1- and T2-classified squamous cell carcinoma (SCC) of the external auditory canal (EAC) even with negative surgical margins. This study aimed to evaluate whether PORT provides additional benefits for these cases. METHODS: We collected retrospective data from fourteen international hospitals, including resected pT1- and pT2-classified EAC SCC with negative surgical margins. RESULTS: A total of 112 early-stage radically resected EAC SCC were included, with 48 patients receiving PORT. The 5-year DFS of T1- and T2-classified EAC SCC treated with PORT was not statistically significantly different (92.9% and 76.9%, respectively) compared to the group treated without PORT (100% and 90.9%, respectively; p-values of 0.999 and 0.526, respectively). EAC SCC treated with PORT more frequently exhibited perineural and angioinvasive growth. Eighteen patients experienced side effects related to radiotherapy, of which one patient developed osteoradionecrosis. CONCLUSIONS: Our study suggests that PORT for early-stage radically resected EAC SCC should only be considered in selected cases with perineural, infiltrative growth or angioinvasive growth, and with a close margin. This approach helps mitigate the negative impact on quality of life and the risk of side effects associated with radiotherapy.
Department of Head and Neck Surgery Lariboisière University Hospital 75010 Paris France
Department of Health Evidence Radboud University Medical Center 6525 GA Nijmegen The Netherlands
Department of Radiation Oncology Radboud University Medical Center 6525 GA Nijmegen The Netherlands
Rare Cancers Radboud Institute for Health Sciences 6525 EZ Nijmegen The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002052
- 003
- CZ-PrNML
- 005
- 20250123102026.0
- 007
- ta
- 008
- 250117s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers16234026 $2 doi
- 035 __
- $a (PubMed)39682212
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Nabuurs, Cindy H $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands $u Rare Cancers, Radboud Institute for Health Sciences, 6525 EZ Nijmegen, The Netherlands $1 https://orcid.org/0000000188944329
- 245 10
- $a Postoperative Radiotherapy for pT1- and pT2-Classified Squamous Cell Carcinoma of the External Auditory Canal / $c CH. Nabuurs, W. Kievit, CRR. Leemans, CFGM. Smit, MWM. van den Brekel, RJ. Pauw, BFAM. van der Laan, JC. Jansen, M. Lacko, WW. Braunius, C. Dai, X. Shi, G. Danesi, J. Bouček, D. Borsetto, S. Gowrishankar, R. Kania, C. Jourdaine, TTG. Jansen, J. Derks, T. Dijkema, RP. Takes, HDPM. Kunst
- 520 9_
- $a BACKGROUND: There is no consensus regarding the indication for postoperative radiotherapy (PORT) for T1- and T2-classified squamous cell carcinoma (SCC) of the external auditory canal (EAC) even with negative surgical margins. This study aimed to evaluate whether PORT provides additional benefits for these cases. METHODS: We collected retrospective data from fourteen international hospitals, including resected pT1- and pT2-classified EAC SCC with negative surgical margins. RESULTS: A total of 112 early-stage radically resected EAC SCC were included, with 48 patients receiving PORT. The 5-year DFS of T1- and T2-classified EAC SCC treated with PORT was not statistically significantly different (92.9% and 76.9%, respectively) compared to the group treated without PORT (100% and 90.9%, respectively; p-values of 0.999 and 0.526, respectively). EAC SCC treated with PORT more frequently exhibited perineural and angioinvasive growth. Eighteen patients experienced side effects related to radiotherapy, of which one patient developed osteoradionecrosis. CONCLUSIONS: Our study suggests that PORT for early-stage radically resected EAC SCC should only be considered in selected cases with perineural, infiltrative growth or angioinvasive growth, and with a close margin. This approach helps mitigate the negative impact on quality of life and the risk of side effects associated with radiotherapy.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kievit, Wietske $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands $u Rare Cancers, Radboud Institute for Health Sciences, 6525 EZ Nijmegen, The Netherlands $u Department of Health Evidence, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
- 700 1_
- $a Leemans, Charles René Reinier $u Department of Otolaryngology-Head and Neck Surgery, Amsterdam University Medical Centers, VU University, 1081 HV Amsterdam, The Netherlands $1 https://orcid.org/000000017887083X
- 700 1_
- $a Smit, Conrad F G M $u Department of Otolaryngology-Head and Neck Surgery, Amsterdam University Medical Centers, VU University, 1081 HV Amsterdam, The Netherlands
- 700 1_
- $a van den Brekel, Michiel W M $u Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $1 https://orcid.org/0000000263386743
- 700 1_
- $a Pauw, Robert J $u Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
- 700 1_
- $a van der Laan, Bernard F A M $u Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center of Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands $u Department of Otorhinolaryngology Head and Neck Surgery, Haaglanden Medical Center, 2512 HH The Hage, The Netherlands $1 https://orcid.org/0000000250162871
- 700 1_
- $a Jansen, Jeroen C $u Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands $1 https://orcid.org/0000000239550152
- 700 1_
- $a Lacko, Martin $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands $1 https://orcid.org/0000000328684822
- 700 1_
- $a Braunius, Weibel W $u Department of Head and Neck Surgical Oncology, University Medical Center, Utrecht Cancer Center, 3584 CG Utrecht, The Netherlands
- 700 1_
- $a Dai, Chunfu $u Department of Otology & Skull Base Surgery, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai 200437, China
- 700 1_
- $a Shi, Xunbei $u Department of Otology & Skull Base Surgery, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai 200437, China
- 700 1_
- $a Danesi, Giovanni $u Department of Otorhinolaryngology and Skull Base Microsurgery-Neurosciences, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, 24127 Bergamo, Italy
- 700 1_
- $a Bouček, Jan $u Department of Otorhinolaryngology, Head and Neck Surgery, The First Faculty of Medicine, Charles University in Prague, University Hospital Motol, 150 06 Prague, Czech Republic
- 700 1_
- $a Borsetto, Daniele $u Department of Otorhinolaryngology, Head and Neck Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
- 700 1_
- $a Gowrishankar, Shavran $u Department of Otorhinolaryngology, Head and Neck Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
- 700 1_
- $a Kania, Romain $u Department of Head and Neck Surgery, Lariboisière University Hospital, 75010 Paris, France
- 700 1_
- $a Jourdaine, Clément $u Department of Head and Neck Surgery, Lariboisière University Hospital, 75010 Paris, France
- 700 1_
- $a Jansen, Thijs T G $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands $u Rare Cancers, Radboud Institute for Health Sciences, 6525 EZ Nijmegen, The Netherlands
- 700 1_
- $a Derks, Jolanda $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
- 700 1_
- $a Dijkema, Tim $u Department of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
- 700 1_
- $a Takes, Robert P $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands $u Rare Cancers, Radboud Institute for Health Sciences, 6525 EZ Nijmegen, The Netherlands
- 700 1_
- $a Kunst, Henricus Dirk P M $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands $u Rare Cancers, Radboud Institute for Health Sciences, 6525 EZ Nijmegen, The Netherlands $u Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 23 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39682212 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123102020 $b ABA008
- 999 __
- $a ok $b bmc $g 2254463 $s 1238055
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 16 $c 23 $e 20241130 $i 2072-6694 $m Cancers $n Cancers (Basel) $x MED00173178
- LZP __
- $a Pubmed-20250117
